Answers are grounded in this paper and cite their sources.
Introduction. The three-drug regimen consisting of docetaxel, cisplatin, and 5-fluorouracil (DCF) has traditionally been regarded as one of the most active neoadjuvant chemotherapy regimens for locally advanced head and neck squamous cell carcinoma. However, its use is associated with a high incidence of treatment-related adverse events. Therefore, the two-drug regimen of docetaxel plus cisplatin (DC) may represent a potential treatment de-escalation strategy for patients with initially resectable oral squamous cell carcinoma. Aim. To compare the short-term antitumor efficacy and toxicity profile of two- versus three-drug taxane-platinum neoadjuvant chemotherapy regimens in patients with resectable locally advanced oral squamous cell carcinoma. Materials and methods. This single-center retrospective cohort study included 45 patients with resectable locally advanced oral squamous cell carcinoma who received neoadjuvant chemotherapy followed by surgery between 2020 and 2026. Twenty-eight patients (62.2 %) received the DCF regimen, whereas 17 (37.8 %) received the DC regimen. Radiological response was assessed according to Response Evaluation Criteria in Solid Tumors 1.1. Pathologic response was classified as pathologic complete response, major pathologic response, or unfavorable pathologic response. Treatment-related toxicity was evaluated using the Common Terminology Criteria for Adverse Events, version 5.0. All patients received primary prophylaxis against chemotherapy-induced neutropenia with epegfilgrastim. Results. The objective response rate was 58.8 % in the DC group and 53.6 % in the DCF group (p = 0.767), whereas disease control rates were 100 and 89.3 %, respectively (p = 0.279). Tumor downstaging (reduction in T category) was observed in 64.7 and 64.3 % of patients, respectively (p = 1.000), while nodal downstaging (reduction in N category) occurred in 17.6 and 21.4 %, respectively (p = 1.000). The complete pathologic response rate was 11.8 % in the DC group and 10.7 % in the DCF group (p = 0.990), whereas the favorable pathologic response rate (complete pathologic response + major pathologic response) was 41.2 and 39.3 %, respectively (p = 1.000). R0 resection was achieved in all patients. Grade 3 adverse events occurred more frequently in the DCF group than in the DC group (53.6 % vs 17.6 %, p = 0.028), primarily because of a higher incidence of grade 3 non-hematological toxicity (42.9 % vs 5.9 %, p = 0.015). No cases of febrile neutropenia were observed. Conclusion. Among patients with resectable locally advanced oral squamous cell carcinoma, no statistically significant differences were observed between the DC and DCF regimens regarding objective response, disease control, tumor and nodal downstaging, pathologic response, or R0 resection rates. The DC regimen was associated with a significantly lower incidence of grade 3 adverse events, primarily owing to reduced non-hematological toxicity. These findings suggest that DC may represent a potential treatment de-escalation strategy for patients with initially resectable oral squamous cell carcinoma.
No takes yet. Share an insight, caveat, or question.
Мусин et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: